MDM4 amplification in a case of de‐differentiated liposarcoma and in‐silico data supporting an oncogenic event alternative to MDM2 amplification in a subset of cases
- 30 July 2017
- journal article
- other
- Published by Wiley in Histopathology
- Vol. 71 (6) , 1019-1023
Abstract
No abstract availableKeywords
Funding Information
- LYRIC (INCa-DGOS-4664)
- LabEx DEvweCAN (ANR-10-LABX-0061)
- Eurosarc (FP7-278742)
This publication has 9 references indexed in Scilit:
- The Mdm Network and Its Regulation of p53 Activities: A Rheostat of Cancer RiskHuman Mutation, 2014
- Vestigial-like 3 is an inhibitor of adipocyte differentiationJournal of Lipid Research, 2013
- The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well‐differentiated and dedifferentiated liposarcoma oncogenesis. An analysis of 104 tumorsGenes, Chromosomes and Cancer, 2011
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapyNature Genetics, 2010
- JUN Oncogene Amplification and Overexpression Block Adipocytic Differentiation in Highly Aggressive SarcomasCancer Cell, 2007
- Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4Cell Death & Differentiation, 2006
- Significance of HDMX‐S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosisInternational Journal of Cancer, 2005
- Complex composition and co‐amplification of SAS and MDM2 in ring and giant rod marker chromosomes in well‐differentiated liposarcomaGenes, Chromosomes and Cancer, 1994
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992